CHAMP1

CHAMP1 is a zinc-finger phosphoprotein that maintains chromosome alignment during mitosis and regulates DNA double-strand break repair pathway choice. During mitosis, CDK1-dependent phosphorylation of CHAMP1 drives its localization to kinetochores and the mitotic spindle via the FPE region, where it stabilizes kinetochore-microtubule attachments and recruits CENP-E and CENP-F; its C-terminal zinc-finger domains mediate binding to POGZ and HP1, forming a complex required for proper chromatin association and mitotic chromosome organization (PMID:21063390, PMID:26751395, PMID:20562864). In DNA repair, CHAMP1 directly binds the REV7 seatbelt domain, competing with the Shieldin subunit SHLD3 to suppress non-homologous end joining and promote homologous recombination through increased end resection, and its overexpression in tumors confers PARP inhibitor resistance (PMID:36044844). De novo loss-of-function mutations truncating the zinc-finger domains cause intellectual disability with severe speech impairment (PMID:26340335).

1. 2010 High

   The fundamental mitotic function of CHAMP1 was established: it localizes to kinetochores and spindles in a CDK1-phosphorylation-dependent manner, maintains kinetochore-microtubule attachment stability, and recruits CENP-E/CENP-F, resolving how a previously uncharacterized phosphoprotein contributes to chromosome alignment.

   Evidence siRNA depletion, live-cell imaging, immunofluorescence, domain deletion/mutagenesis, and co-immunoprecipitation in human cells

   PMID:21063390

   Open questions at the time

   • Direct structural basis for FPE-mediated kinetochore targeting is unknown
   • How CDK1 phosphorylation counteracts the zinc-finger inhibitory domain at the atomic level is unresolved
   • Whether CHAMP1 interacts directly with CENP-E/CENP-F or acts indirectly was not determined
2. 2010 High

   The identification of POGZ as an HP1α-binding protein that regulates HP1α dissociation from mitotic chromosomes and Aurora B activation established the chromatin regulatory axis into which CHAMP1 integrates via its POGZ interaction.

   Evidence Proteomics, reciprocal co-immunoprecipitation, domain mapping of HP1α binding, and siRNA phenotype analysis

   PMID:20562864

   Open questions at the time

   • CHAMP1's direct contribution to HP1α displacement and Aurora B regulation was not tested in this study
   • Stoichiometry and assembly order of the CHAMP1–POGZ–HP1 complex are undefined
3. 2015 Medium

   The in vivo significance of CHAMP1's zinc-finger-dependent chromosomal functions was demonstrated when de novo truncating mutations were shown to cause intellectual disability, establishing CHAMP1 as a disease gene and linking its mitotic/chromosomal role to neurodevelopment.

   Evidence Trio whole-exome sequencing in patients with intellectual disability; domain-level functional inference

   PMID:26340335

   Open questions at the time

   • No functional rescue experiment was performed to confirm causality
   • Whether the neurodevelopmental phenotype arises from mitotic defects, interphase chromatin dysfunction, or both is unknown
   • Animal model validation was not reported
4. 2016 High

   The molecular mechanism of disease-associated CHAMP1 mutations was clarified: truncation of the zinc-finger domains abolishes binding to both POGZ and HP1, causing protein delocalization from chromatin and establishing these interactions as the critical determinants of CHAMP1 chromosomal association.

   Evidence Co-immunoprecipitation of wild-type and mutant CHAMP1 with POGZ and HP1; immunofluorescence localization of mutant proteins

   PMID:26751395

   Open questions at the time

   • Whether POGZ binding and HP1 binding are independent or cooperative is not resolved
   • Contribution of individual zinc-finger repeats to each interaction has not been mapped
5. 2022 High

   A second major function of CHAMP1 was uncovered: direct binding to the REV7 seatbelt domain displaces the Shieldin complex, promoting DNA end resection and homologous recombination, thereby establishing CHAMP1 as a molecular switch between NHEJ and HR repair pathways with implications for PARP inhibitor resistance.

   Evidence Co-immunoprecipitation, CRISPR/siRNA loss-of-function, end-resection assays, PARP inhibitor sensitivity assays, and tumor expression analysis

   PMID:36044844

   Open questions at the time

   • Structural basis of CHAMP1–REV7 seatbelt interaction at atomic resolution is lacking
   • Whether the mitotic (POGZ–HP1) and DNA repair (REV7–Shieldin) functions of CHAMP1 are coordinated or independent remains untested
   • In vivo validation of CHAMP1-driven PARPi resistance in preclinical tumor models has not been reported

• It remains unknown how the mitotic chromosome alignment function and the DNA repair pathway-switching function of CHAMP1 are coordinated, whether they are cell-cycle-phase-specific, and how loss of both activities contributes to the neurodevelopmental phenotype of CHAMP1-related intellectual disability.
• No cell-cycle-resolved separation-of-function analysis exists for CHAMP1's mitotic versus DNA repair roles
• No animal model recapitulating CHAMP1 loss-of-function neurodevelopmental phenotypes has been published
• The relative contribution of POGZ–HP1 axis versus REV7–Shieldin axis to CHAMP1 disease phenotypes is undefined